Last reviewed 2026-06-02 · How we verify

Paxlovid (Copackaged) (nirmatrelvir)

Paxlovid (Copackaged) (generic name: nirmatrelvir) is a drug developed by Pfizer. It is currently FDA-approved (first approved 2023) for Treatment of mild-to-moderate COVID-19.

Paxlovid works by binding to the main protease enzyme of the SARS-CoV-2 virus, preventing it from replicating.

Paxlovid, a medication developed by Pfizer, is a combination of nirmatrelvir and ritonavir used to treat COVID-19. Nirmatrelvir, the active component of Paxlovid, acts as an orally active 3C-like protease inhibitor.

At a glance

Mechanism of action

Imagine the virus as a factory that produces copies of itself. Paxlovid is like a key that locks the factory door, stopping the virus from making more copies. This helps the body's immune system fight off the infection more effectively.

Approved indications

• Treatment of mild-to-moderate COVID-19

Boxed warnings

• WARNING: SIGNIFICANT DRUG INTERACTIONS WITH PAXLOVID • PAXLOVID includes ritonavir, a strong CYP3A inhibitor, which may lead to greater exposure of certain concomitant medications, resulting in potentially severe, life-threatening, or fatal events [see Contraindications (4) , Warnings and Precautions (5.1) , and Drug Interactions (7) ]. • Prior to prescribing PAXLOVID: 1) Review all medications taken by the patient to assess potential drug-drug interactions with a strong CYP3A inhibitor like PAXLOVID and 2) Determine if concomitant medications require a dose adjustment, interruption, and/or additional monitoring [see Drug Interactions (7) ]. • Consider the benefit of PAXLOVID treatment in reducing hospitalization and death, and whether the risk of potential drug-drug interactions for an individual patient can be appropriately managed [see Warnings and Precautions (5.1) , Drug Interactions (7) , and Clinical Studies (14) ]. WARNING: SIGNIFICANT DRUG INTERACTIONS WITH PAXLOVID See full prescribing information for complete boxed warning. • PAXLOVID includes ritonavir, a strong CYP3A inhibitor, which may lead to greater exposure of certain concomitant medications, resulting in potentially severe, life-threatening, or fatal events. ( 4 , 5.1 , 7 ) • Prior to prescribing PAXLOVID: 1) Review all medications taken by the patient to assess potential drug-drug interactions with a strong CYP3A inhibitor like PAXLOVID and 2) Determine if concomitant medications require a dose adjustment, interruption, and/or additional monitoring. ( 7 ) • Consider the benefit of PAXLOVID treatment in reducing hospitalization and death, and whether the risk of potential drug-drug interactions for an individual patient can be appropriately managed. ( 5.1 , 7 , 14 )

Common side effects

• Drug interaction
• Acute kidney injury
• Toxicity to various agents

Key clinical trials

• RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms (PHASE2)
• OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial (PHASE2)
• Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PHASE2)
• OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients (PHASE2)
• Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
• A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
• Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19 (PHASE2)
• AGILE (Early Phase Platform Trial for COVID-19) (PHASE1,PHASE2)

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Paxlovid (Copackaged) CI brief — competitive landscape report
• Paxlovid (Copackaged) updates RSS · CI watch RSS
• Pfizer portfolio CI

Frequently asked questions about Paxlovid (Copackaged)

Related

• Manufacturer: Pfizer — full pipeline
• Therapeutic area: All drugs in Immunology
• Indication: Drugs for Treatment of mild-to-moderate COVID-19

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing